HEALTH: Lilly Alzheimer’s drug fails in latest study.

The drug, solanezumab, missed the study’s main goal of significantly slowing cognitive decline in patients compared to a placebo or fake drug.

Eli Lilly and Co. had been studying the drug in patients with mild cases of the disease.

Current Alzheimer’s treatments like Aricept and Namenda only temporarily ease symptoms such as memory loss, confusion and agitation. They don’t slow, stop or reverse the mental decline that happens when the brain’s nerve cells stop functioning normally.

Faster, please.